JP2004536107A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004536107A5 JP2004536107A5 JP2003510065A JP2003510065A JP2004536107A5 JP 2004536107 A5 JP2004536107 A5 JP 2004536107A5 JP 2003510065 A JP2003510065 A JP 2003510065A JP 2003510065 A JP2003510065 A JP 2003510065A JP 2004536107 A5 JP2004536107 A5 JP 2004536107A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- agent
- subunit
- truncated
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 39
- 239000003795 chemical substances by application Substances 0.000 claims 24
- 108091026890 Coding region Proteins 0.000 claims 15
- 230000001580 bacterial effect Effects 0.000 claims 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims 9
- 239000002095 exotoxin Substances 0.000 claims 9
- 231100000776 exotoxin Toxicity 0.000 claims 9
- 239000002245 particle Substances 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 210000004962 mammalian cell Anatomy 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 102000009016 Cholera Toxin Human genes 0.000 claims 2
- 108010049048 Cholera Toxin Proteins 0.000 claims 2
- 101710146739 Enterotoxin Proteins 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 239000000147 enterotoxin Substances 0.000 claims 2
- 231100000655 enterotoxin Toxicity 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000013600 plasmid vector Substances 0.000 claims 2
- 238000001890 transfection Methods 0.000 claims 2
- 102000009062 ADP Ribose Transferases Human genes 0.000 claims 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 claims 1
- 101710082714 Exotoxin A Proteins 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72431500A | 2000-11-27 | 2000-11-27 | |
| PCT/US2001/043151 WO2003004055A2 (en) | 2000-11-27 | 2001-11-26 | Nucleic acid adjuvants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004536107A JP2004536107A (ja) | 2004-12-02 |
| JP2004536107A5 true JP2004536107A5 (enExample) | 2005-12-22 |
| JP4221289B2 JP4221289B2 (ja) | 2009-02-12 |
Family
ID=24909936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003510065A Expired - Fee Related JP4221289B2 (ja) | 2000-11-27 | 2001-11-26 | 核酸アジュバント |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1379273B1 (enExample) |
| JP (1) | JP4221289B2 (enExample) |
| KR (1) | KR20040045391A (enExample) |
| CN (1) | CN1317034C (enExample) |
| AT (1) | ATE442858T1 (enExample) |
| AU (1) | AU2001297988B2 (enExample) |
| BR (1) | BR0115646A (enExample) |
| CA (1) | CA2429708A1 (enExample) |
| DE (1) | DE60139959D1 (enExample) |
| DK (1) | DK1379273T3 (enExample) |
| ES (1) | ES2332261T3 (enExample) |
| IL (2) | IL156041A0 (enExample) |
| MX (1) | MXPA03004638A (enExample) |
| NZ (1) | NZ526175A (enExample) |
| PT (1) | PT1379273E (enExample) |
| WO (1) | WO2003004055A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0415204A (pt) | 2003-10-10 | 2006-12-05 | Powderject Vaccines Inc | construção de ácido nucleico, métodos de obtenção da expressão em células de mamìferos de um polipeptìdeo de interesse, e de imunização com ácido nucleico, partìculas revestidas, receptáculo de dosagem para um dispositivo de liberação mediada por partìculas, dispositivo de liberação mediada por partìculas, e, sequência de promotor quimérico isolada purificada |
| ATE555127T1 (de) | 2004-02-11 | 2012-05-15 | Angeletti P Ist Richerche Bio | Fusionsproteine des karzinomembryonalen antigens und deren verwendungen |
| GB0507997D0 (en) * | 2005-02-01 | 2005-05-25 | Powderject Vaccines Inc | Nucleic acid constructs |
| EP2286824B1 (en) * | 2008-05-07 | 2013-08-14 | Osaka University | Non-covalent crosslinking agent for collagen |
| AU2011302645B2 (en) | 2010-09-15 | 2015-02-26 | Applied Molecular Transport, Llc | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| CN103060253A (zh) * | 2013-01-24 | 2013-04-24 | 麻丽丹 | 霍乱弧菌ctxAB基因的质粒克隆菌株以及制备方法和应用 |
| KR20230154480A (ko) | 2014-05-07 | 2023-11-08 | 어플라이드 몰레큘라 트랜스포트 인크. | 생물학적 활성 화물의 경구 전달용 콜릭스 독소-유래 융합 분자 |
| PL3762009T3 (pl) | 2018-03-08 | 2022-09-12 | Applied Molecular Transport Inc. | Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego |
| EP4083058A3 (en) | 2018-11-07 | 2023-01-11 | Applied Molecular Transport Inc. | Delivery constructs for transcytosis and related methods |
| KR20220066056A (ko) | 2019-08-16 | 2022-05-23 | 어플라이드 몰레큘라 트랜스포트 인크. | 조성물, 제형, 및 인터루킨 제조 및 정제 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| TW404844B (en) | 1993-04-08 | 2000-09-11 | Oxford Biosciences Ltd | Needleless syringe |
| GB9416663D0 (en) | 1994-08-17 | 1994-10-12 | Oxford Bioscience Limited | Particle delivery |
| JP3853360B2 (ja) | 1994-10-24 | 2006-12-06 | パウダージェクト リサーチ リミテッド | 粒子供給装置 |
| GB9426379D0 (en) | 1994-12-23 | 1995-03-01 | Oxford Biosciences Ltd | Particle delivery |
| US6056960A (en) * | 1995-06-07 | 2000-05-02 | Kaslow; Harvey R. | Compositions exhibiting ADP-ribosyltransferase activity and methods for the preparation and use thereof |
| GB9612629D0 (en) | 1996-06-17 | 1996-08-21 | Oxford Biosciences Ltd | Method for providing dense particle compositions for use in transdermal particle delivery |
| US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
-
2001
- 2001-11-26 DK DK01274277T patent/DK1379273T3/da active
- 2001-11-26 CA CA002429708A patent/CA2429708A1/en not_active Abandoned
- 2001-11-26 NZ NZ526175A patent/NZ526175A/en unknown
- 2001-11-26 CN CNB018195709A patent/CN1317034C/zh not_active Expired - Fee Related
- 2001-11-26 IL IL15604101A patent/IL156041A0/xx unknown
- 2001-11-26 JP JP2003510065A patent/JP4221289B2/ja not_active Expired - Fee Related
- 2001-11-26 KR KR10-2003-7007121A patent/KR20040045391A/ko not_active Ceased
- 2001-11-26 ES ES01274277T patent/ES2332261T3/es not_active Expired - Lifetime
- 2001-11-26 AU AU2001297988A patent/AU2001297988B2/en not_active Ceased
- 2001-11-26 MX MXPA03004638A patent/MXPA03004638A/es active IP Right Grant
- 2001-11-26 PT PT01274277T patent/PT1379273E/pt unknown
- 2001-11-26 AT AT01274277T patent/ATE442858T1/de active
- 2001-11-26 WO PCT/US2001/043151 patent/WO2003004055A2/en not_active Ceased
- 2001-11-26 EP EP01274277A patent/EP1379273B1/en not_active Expired - Lifetime
- 2001-11-26 DE DE60139959T patent/DE60139959D1/de not_active Expired - Lifetime
- 2001-11-26 BR BR0115646-2A patent/BR0115646A/pt not_active Application Discontinuation
-
2003
- 2003-05-21 IL IL156041A patent/IL156041A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1097213B1 (en) | Vaccine against staphylococcus intoxication | |
| ES2139879T5 (es) | Adyuvante de la mucosa no toxico. | |
| US7335369B2 (en) | Fusion proteins of mycobacterium tuberculosis antigens and their uses | |
| US20150266934A1 (en) | Methods for protection against lethal infection with bacillus anthracis | |
| JP2004527213A5 (enExample) | ||
| EP0919243A1 (en) | Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant | |
| HU228354B1 (en) | Fusion proteins of mycobacterium tuberculosis antigens and their uses | |
| US20080248068A1 (en) | Use of Flagellin as an Adjuvant for Vaccine | |
| US8834896B2 (en) | Vault compositions for immunization | |
| Wortham et al. | Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2 | |
| JP2004536107A5 (enExample) | ||
| US8143386B2 (en) | Fusion proteins of mycobacterium tuberculosis antigens and their uses | |
| US7064195B2 (en) | Fusion proteins of mycobacterium tuberculosis antigens and their uses | |
| Mohapatra | Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus | |
| JP4875497B2 (ja) | バクテリオファージナノ粒子を含む方法および組成物 | |
| JP2002528123A5 (enExample) | ||
| Delman et al. | Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer | |
| EP1143934B1 (en) | Genetic immunization with co-delivery of nucleic acid and cytokines | |
| WO2008048289A2 (en) | Salmonella based oral vaccines for anthrax | |
| TW528760B (en) | Peptide repeat immunogens | |
| CN120500351A (zh) | 呼吸道合胞病毒mRNA疫苗 | |
| US20040082530A1 (en) | Nucleic acid immunization | |
| Xie et al. | Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency | |
| JP6216371B2 (ja) | ＹｅｒｓｉｎｉａｐｅｓｔｉｓＦ１−Ｖ融合タンパク質を発現するＳａｌｍｏｎｅｌｌａＴｙｐｈｉＴｙ２１ａおよびその使用 | |
| Dabaghian et al. | Use of N-trimethyl chitosan for intranasal delivery of DNA encoding M2e-HSP70c in mice |